» Articles » PMID: 8402693

Quantitative Comparison Between the Transplantability of Human and Murine Tumors into the Brain of NCr/Sed-nu/nu Nude and Severe Combined Immunodeficient Mice

Overview
Journal Cancer Res
Specialty Oncology
Date 1993 Oct 15
PMID 8402693
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

We have demonstrated (A. Taghian et al., Cancer Res., 53: 5012-5017, 1993) that the take rate of human xenografts in the s.c. tissue of severe combined immunodeficient (SCID) mice is significantly higher than that of nude mice. Earlier, this laboratory reported that the transplantability of tumor xenografts was significantly higher for intracranial (i.c.) injection than for s.c. injection in nude mice. The purpose of this study is to assess: (a) the relative i.c. transplantability of human and murine tumors in comparison with s.c. tissue in SCID mice; (b) the relative i.c. transplantability in SCID mice in comparison to nude mice; and (c) the influence of whole-body irradiation on i.c. transplantability of SCID and nude mice. The assay based on the number of cells required to transplant tumors into 50% of recipients (TD50) was used to describe the transplantability assays. Five human and four murine tumor cell lines were used. Concurrent TD50 assays were performed i.c. in whole-body irradiated and nonirradiated SCID and nude mice. Serial 2-10-fold dilutions of cells were injected in a 10-microliters volume into the right parietal lobe 3 mm below the skin. The results showed that in all tumors studied the i.c. TD50S were significantly lower than the s.c. TD50S by a factor of 1.7-1580. The average enhancement ratio (s.c. TD50/i.c. TD50) in nude mice was twice that in SCID mice. No significant difference was found between the i.c. TD50S in SCID and in nude mice, contrary to the significant difference in s.c. TD50S between both strains of mice (A. Taghian et al., Cancer Res., 53: 5012-5017, 1993). Whole-body irradiation did not significantly affect the i.c. TD50 in nude mice; however, it did affect two of three xenografts in SCID mice. In conclusion, despite the significantly lower s.c. TD50S of human xenografts in SCID mice, i.c. TD50S were almost similar to those of NCr/Sed-nu/nu nude mice. This suggests the presence of different immunoreactivities between nude and SCID mice in s.c. transplantability; however, for i.c. transplantability, nude mice behaved equally as well as SCID mice. The significant enhancement ratio in SCID mice is further evidence that this strain of mice displays a residual systemic immunoreactivity, although the immunoreactivity is significantly lower than that of nude mice.

Citing Articles

Advances and Hurdles in CAR T Cell Immune Therapy for Solid Tumors.

Boccalatte F, Mina R, Aroldi A, Leone S, Suryadevara C, Placantonakis D Cancers (Basel). 2022; 14(20).

PMID: 36291891 PMC: 9600451. DOI: 10.3390/cancers14205108.


Comparison of Genetically Engineered Immunodeficient Animal Models for Nonclinical Testing of Stem Cell Therapies.

Kim Y, Kim J, Che J, Ku S, Kang B, Yun J Pharmaceutics. 2021; 13(2).

PMID: 33498509 PMC: 7909568. DOI: 10.3390/pharmaceutics13020130.


Potential role of natural killer cells in controlling growth and infiltration of AIDS-associated primary effusion lymphoma cells.

Zahidunnabi Dewan M, Terunuma H, Toi M, Tanaka Y, Katano H, Deng X Cancer Sci. 2006; 97(12):1381-7.

PMID: 16995875 PMC: 11158791. DOI: 10.1111/j.1349-7006.2006.00319.x.


The combination of adenoviral HSV TK gene therapy and radiation is effective in athymic mouse glioblastoma xenografts without increasing toxic side effects.

Nestler U, Wakimoto H, Siller-Lopez F, Aguilar L, Chakravarti A, Muzikansky A J Neurooncol. 2004; 67(1-2):177-88.

PMID: 15072465 DOI: 10.1023/b:neon.0000021897.53969.ca.


Human glioma cells transformed by IGF-I triple helix technology show immune and apoptotic characteristics determining cell selection for gene therapy of glioblastoma.

Ly A, Duc H, Kalamarides M, Trojan L, Pan Y, Shevelev A Mol Pathol. 2001; 54(4):230-9.

PMID: 11477137 PMC: 1187073. DOI: 10.1136/mp.54.4.230.